Skip to main content

Table 1 Outcome measures in the MONITOR-PsA cohort study

From: Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design

Procedures Visits
Baseline cohort        
Week 0 Week 12 Week 24 Week 36 Week 48 Week 72 Week 96 Annually (after 96 weeks)
Informed consent X        
Demographics X        
Medical history X X X X X X X X
Medications X X X X X X X X
Physical examination X X X X X X X X
Routine blood tests (FBC, U&Es, LFTs, CRP and eGFR) X X X X X X X X
Immunology (RF, ACPA, ANA) X        
Radiographs of hands/feet/spine X     X   X X
Eligibility assessment X        
Adherence   X X X X X X X
68/66 Joint count X X X X X X X X
Leeds and SPARCC enthesitis index X X X X X X X X
Dactylitis count X X X X X X X X
Psoriasis assessment (PASI and BSA) X X X X X X X X
Physician VAS X X X X X X X X
Metrology with BASMI (if axial involvement) X     X   X X
Patient questionnaires (VAS, HAQ, SF36, PsAID, WPAI, BASDAI, BASFI) X X X X X X X X
TSQM questionnaire   X X X X X X X
EQ-5D-5L questionnaire X   X   X X X X
Healthcare utilisation data    X   X X X X
Adverse event assessments X X X X X X X X